PE & Banking Experts Join Business Advisory Board

Turn Therapeutics is pleased to announce the additions of Jeffrey Bunder and Peter Gould to our business advisory board.

With these two incredible additions, the business advisory board is complete and will begin meetings in the near future to assist management in incorporating governance, financing, banking, and development plans to suit those of a company at our stage intending to publicly list. The skillsets of this group include deep pharmaceutical, M&A, investment, and banking expertise, as well as decades of operational experience in the private and public markets. Their faith in our future is a true honor.  

Jeffrey Bunder

Jeff is a seasoned financial and investment professional with extensive experience in private equity, corporate finance, and transaction advisory. He spent over two decades at Ernst & Young (EY), where he served as the Global Private Equity Leader, advising some of the world’s largest private equity firms on deal structuring, fundraising, and portfolio optimization.

During Jeff’s tenure at EY, he played a key role in shaping the firm’s private equity strategy, providing insights on industry trends, regulatory developments, and investment strategies. His expertise spans across mergers and acquisitions, capital markets, and operational improvements within companies. His leadership, experience, and kindness will make him an invaluable member of the Turn Therapeutics family.

Peter Gould

Peter Gould is a Managing Director at J.P. Morgan Private Bank, bringing over 30 years of banking experience spanning asset-based lending, commercial banking, investment banking, and private banking. His specific expertise lies in complex credit structures, capital markets, and strategic financial solutions. 

Prior to joining J.P. Morgan, Peter spent 12 years as a Managing Director at Wells Fargo’s Abbot Downing division, where he specialized in structured lending and credit solutions for clients across the Western U.S. Before that, he held leadership roles at Citibank, Bank of America, and Bank of America Securities, with experience in investment banking, corporate finance, and risk management.

Beyond banking, Peter is actively involved in community service. He currently serves as Chairman of the Board for Interface Children & Family Services, a Ventura County nonprofit focused on family resources, violence prevention, and support services. He is also a former board member of organizations such as the Boys & Girls Clubs of Long Beach. Who he is, what he’s done, and what Peter means to Turn Therapeutics make formally appointing him a business advisor both an honor and a pleasure.

Related News

Muhammad Zubair

Controller

Zubair, Controller, has 5+ years of accounting and finance management experience in companies ranging from medium-sized companies to pulicly traded multinationals. Zubair is a member of the Institute of Chartered Accountants of Pakistan and holds a Master’s degree in accounting & finance (Equivalent). 

Zuraiz Chaudhary, CPA

Chief Accounting Officer, VP Finance

Zuraiz, VP of Finance and Chief Accounting Officer, is a seasoned finance & accounting executive with more than a decade experience in working with PwC, EY and KPMG.  Zuraiz is a licensed CPA in California and Texas, has a bachelor’s in business administration from Asia-e University (Malaysia), is a member of the Institute of Chartered Accountants of Pakistan. Zuraiz specializes in financial reporting, SOX compliance and internal controls.

Dr. Neil Ghodadra, MD

Chief Medical Officer, Board Director

Dr. Neil Ghodadra, Board Certified Orthopedic Surgeon, joined Turn in Q3 2017. Renowned for surgical skill and orthopedic research, he graduated Magna Cum Laude from Duke University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery.

Bradley Burnam

Chief Executive Officer & Founder

Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn’s flagship product. Burnam, a self-taught regulatory and formulation expert, secured Turn’s first three FDA clearances solo before assembling a skilled team.

Subscribe to the Founder's Blog

Enter your information to subscribe for the latest updates from our Founder’s Blog.

Sign Up for Updates

Enter your information to receive the latest product updates and news from Turn Therapeutics.